Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.
Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars.
Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars. The biosimilars arena presents significant opportunities and both companies are set on finding the best routes to realizing the benefits that safe biosimilars of certain biologic pharmaceuticals will bring to the society.
There is, however, significant regulatory uncertainty with biosimilars at present. Teva and Lonza are, therefore, taking a measured approach. Both companies have agreed to fully evaluate the prevailing regulatory and commercial circumstances before making any further long-term investment decisions on their joint venture.
